The grant is for £1.3m and will begin in late spring, so a number of postdoc job opportunities will appear soon. The research explores in particular developments in cell therapies, to track the interplay between corporations clinics and regulators, especially in regard to perceptions of its clinical utility, and the patterns of regulatory oversight that are seen to be needed. We hope thereby to determine the current and potential impact of the field on health and healthcare systems and how these in turn shape its development.
The work builds on previous work in SATSU - the REMEDIE project - funded by the European Commission and a national ESRC programme on stem cells that Andrew coordinated. Andrew recently gave a presentation to the All Party Parliamentary Group for Social Science and Policy on the issues raised for the NHS. Meanwhile SATSU's doctoral researcher, Ruchhi Higham, is also working in the area examining the ways the field disrupts conventional approaches to clinical trials.
More generally, this research ties in with the European Commission-funded COST Action called 'Bio-objects', that Andrew also Chairs.